Literature DB >> 11300426

Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects.

H P Brunner-La Rocca1, D M Kaye, R L Woods, J Hastings, M D Esler.   

Abstract

OBJECTIVES: We sought to assess the effects of brain natriuretic peptide (BNP) on systemic and regional sympathetic nervous activity (SNA) in both patients with congestive heart failure (CHF) and healthy control subjects.
BACKGROUND: Although the response of SNA to atrial natriuretic peptide (ANP) has been well documented, the response of SNA to BNP is largely unknown.
METHODS: We assessed cardiac and whole-body SNA using the norepinephrine (NE) tracer dilution method before and after infusion of two doses of BNP (3 and 15 ng/kg body weight per min) in 11 patients with stable CHF (ejection fraction 24 +/- 2%) and 12 age-matched healthy control subjects. In addition, renal SNA and hemodynamic variables were assessed at baseline and after the higher BNP dose.
RESULTS: Low dose BNP did not change blood pressure or whole-body NE spillover, but reduced cardiac NE spillover in both groups by 32 +/- 13 pmol/min (p < 0.05). In both groups, high dose BNP reduced pulmonary capillary pressure by 5 +/- 1 mm Hg (p < 0.001) and mean arterial pressure by 6 +/- 3 mm Hg (p < 0.05), without a concomitant increase in whole-body NE spillover; however, cardiac NE spillover returned to baseline levels. Renal NE spillover remained virtually unchanged in healthy control subjects (501 +/- 120 to 564 +/- 115 pmol/min), but was reduced in patients with CHF (976 +/- 133 to 656 +/- 127 pmol/min, p < 0.01).
CONCLUSIONS: Our results demonstrate a sympathoinhibitory effect of BNP. Cardiac sympathetic inhibition was observed at BNP concentrations within the physiologic range, whereas high dose BNP, when arterial and filling pressures fell and reflex sympathetic stimulation was expected, systemic and cardiac SNA equated to baseline values. There was inhibition of renal SNA in patients with CHF, but not in healthy control subjects. Whether this effect is specific to BNP or related to reduced filling pressure remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11300426     DOI: 10.1016/s0735-1097(01)01172-x

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  56 in total

Review 1.  Are There Deleterious Cardiac Effects of Acute and Chronic Endurance Exercise?

Authors:  Thijs M H Eijsvogels; Antonio B Fernandez; Paul D Thompson
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

Review 2.  Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure.

Authors:  Chaitanya Madamanchi; Hassan Alhosaini; Arihiro Sumida; Marschall S Runge
Journal:  Int J Cardiol       Date:  2014-08-09       Impact factor: 4.164

Review 3.  Nesiritide for acute decompensated heart failure: does the benefit justify the risk?

Authors:  Jonathan Sackner-Bernstein; Keith D Aaronson
Journal:  Curr Cardiol Rep       Date:  2007-05       Impact factor: 2.931

Review 4.  Benefit-risk assessment of nesiritide in the treatment of acute decompensated heart failure.

Authors:  Clyde W Yancy
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

5.  Evaluation of cardiac sympathetic nerve activity and aldosterone suppression in patients with acute decompensated heart failure on treatment containing intravenous atrial natriuretic peptide.

Authors:  Shu Kasama; Takuji Toyama; Toshiya Iwasaki; Hiroyuki Sumino; Hisao Kumakura; Kazutomo Minami; Shuichi Ichikawa; Naoya Matsumoto; Tomoaki Nakata; Masahiko Kurabayashi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-09       Impact factor: 9.236

Review 6.  Cyclic nucleotide regulation of cardiac sympatho-vagal responsiveness.

Authors:  Dan Li; David J Paterson
Journal:  J Physiol       Date:  2016-05-05       Impact factor: 5.182

7.  Sympathetic overactivity in patients with rheumatic mitral stenosis.

Authors:  Ozcan Ozdemir; Omer Alyan; Mustafa Soylu; Fatma Metin; Ahmet Duran Demir; Bilal Geyik; Dursun Aras; Cemal Ozbakir; Gökhan Cihan; Hatice Sasmaz; Sule Korkmaz
Journal:  Ann Noninvasive Electrocardiol       Date:  2004-10       Impact factor: 1.468

Review 8.  Percutaneous Creation of a Central Iliac Arteriovenous Anastomosis for the Treatment of Arterial Hypertension.

Authors:  Stefan C Bertog; Nathan A Sobotka; Paul A Sobotka; Melvin D Lobo; Kolja Sievert; Laura Vaskelyte; Horst Sievert; Roland E Schmieder
Journal:  Curr Hypertens Rep       Date:  2018-03-19       Impact factor: 5.369

9.  Efficacy of B-Type Natriuretic Peptide Is Coupled to Phosphodiesterase 2A in Cardiac Sympathetic Neurons.

Authors:  Dan Li; Chieh-Ju Lu; Guoliang Hao; Hannah Wright; Lavinia Woodward; Kun Liu; Elisa Vergari; Nicoletta C Surdo; Neil Herring; Manuela Zaccolo; David J Paterson
Journal:  Hypertension       Date:  2015-04-27       Impact factor: 10.190

10.  Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study.

Authors:  H H Chen; F L Martin; R J Gibbons; J A Schirger; R S Wright; R M Schears; M M Redfield; R D Simari; A Lerman; A Cataliotti; J C Burnett
Journal:  Heart       Date:  2009-05-15       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.